Evidence map›Paper›PMID 15479813›Full record

ArticleJournal of virology2004

A novel approach for producing lentiviruses that are limited to a single cycle of infection.

David T Evans, Jennifer E Bricker, Ronald C Desrosiers

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2017
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha.Proceedings of the National Academy of Sciences of the United States of America · 2006
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David T EvansNew England Primate Research Center, Harvard Medical School, Southborough, Massachusetts, USA. dte@u.washington.edu.
Jennifer E Bricker
Ronald C Desrosiers
Harvard University · USNew England Biolabs (United States) · US

Funding

PROTECTIVE EFFICACY OF LIVE ATTENUATED SIV VACCINESP01AI035365 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DESROSIERS, RONALD C · 1998 to 2004
$8.5M
Single-Cycle SIV as a Non-Replicating Vaccine StrainK22AI052751 · NIAID · UNIVERSITY OF WASHINGTON · PI EVANS, DAVID T · 2003 to 2004
$270k
MUCOSAL TRANSMISSION OF SINGLE-CYCLE SIV RECOMBINANTSF32AI010464 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI EVANS, DAVID T · 2000 to 2002
$128k
SAFETY AND EFFICACY OF LIVE ATTENUATED SIV DELETION MUTANTSU01AI035365 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · 1994 to 1998
–
NIAID NIH HHS AI10464NIAID NIH HHS AI35365NIAID NIH HHS AI52751NIAID NIH HHS F32 AI010464NIAID NIH HHS K22 AI052751NIAID NIH HHS P01 AI035365NIAID NIH HHS U01 AI035365
6 · The paper itself

Abstract

We have devised a novel approach for producing simian immunodeficiency virus (SIV) strains and, potentially, human immunodeficiency virus type 1 (HIV-1) strains that are limited to a single cycle of infection. Unlike previous lentiviral vectors, our single-cycle SIV is capable of expressing eight of the nine viral gene products and infected cells release immature virus particles that are unable to complete subsequent rounds of infection. Single-cycle SIV (scSIV) was produced by using a two-plasmid system specifically designed to minimize the possibility of generating replication-competent virus by recombination or nucleotide reversion. One plasmid carried a full-length SIV genome with three nucleotide substitutions in the gag-pol frameshift site to inactivate Pol expression. To ensure inactivation of Pol and to prevent the recovery of wild-type virus by nucleotide reversion, deletions were also introduced into the viral pol gene. In order to provide Gag-Pol in trans, a Gag-Pol-complementing plasmid that included a single nucleotide insertion to permanently place gag and pol in the same reading frame was constructed. We also mutated the frameshift site of this Gag-Pol expression construct so that any recombinants between the two plasmids would remain defective for replication. Cotransfection of both plasmids into 293T cells resulted in the release of Gag-Pol-complemented virus that was capable of one round of infection and one round of viral gene expression but was unable to propagate a spreading infection. The infectivity of scSIV was limited by the amount of Gag-Pol provided in trans and was dependent on the incorporation of a functional integrase. Single-cycle SIV produced by this approach will be useful for addressing questions relating to viral dynamics and viral pathogenesis and for evaluation as an experimental AIDS vaccine in rhesus macaques.

Indexed as

Amino Acid SequenceAnimalsBase SequenceCell LineFrameshift MutationFusion Proteins, gag-polGenes, polGenes, vifHumansMacaca mulattaMacrophagesMolecular Sequence DataSimian Immunodeficiency VirusT-LymphocytesVirionVirus ReplicationFusion Proteins, gag-pol

Identifiers

PMID15479813
PMCPMC523244
OpenAlexW2143625219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.